P16和CD44在胃肠间质瘤中的表达及其与预后的关系  

Expression of P16 and CD44 in gastrointestinal stromal tumors and their relationship with the prognosis of patients

作　　者：史恩溢[1] 王晓茹[1] 李小宁[1] 蔡旭[2] 朱雄增[2] 

机构地区：[1]苏州卫生职业技术学院病理教研室,215009 [2]复旦大学附属肿瘤医院病理科,200032

出　　处：《实用医学杂志》2016年第14期2333-2337,共5页The Journal of Practical Medicine

基　　金：江苏省卫生职业技术研究项目(编号:J201102)

摘　　要：目的：探讨P16和CD44在胃肠间质瘤（GIST）中的表达及其与预后关系。方法：收集70例手术切除的GIST标本,构建组织芯片。免疫组织化学染色方法检测P16和CD44的表达情况。患者采用门诊和电话随访。结果：所有患者随访2-212个月,中位随访时间68个月。P16表达与GIST NIH危险度分级无关（P〉0.05）,而CD44表达与GIST NIH危险度分级有关（P〈0.05）。单因素生存分析结果显示,肿瘤直径、核分裂像、原发部位、NIH危险度分级、P16和CD44表达与患者预后相关;多因素生存分析结果显示,肿瘤直径、核分裂像、原发部位和CD44是影响患者独立预后的危险因素。结论：CD44蛋白表达可以作为判断GIST患者预后的重要指标。Objective To investigate the expression of P16 and CD44 in gastrointestinal stromal tumors（GIST） and their relationship with the prognosis of patients. Methods The GIST specimens of seventy patients who received surgical excision were collected. Tissue microarray of the seventy GIST samples was constructed.The expression of P16 and CD44 were detected by the immunohistochemical staining. The patients were followed up via out-patient examination and telephone. Results All the patients were followed up for 2-212 months,and the median time for follow-up was 68 months. The differences of the expression of P16 in GISTs among NIH risk ranks were insignificant（P〈 0.05）. The differences of the expression of CD44 in GISTs among NIH risk ranks were statistically significant（P〈 0.05）. Univariate analysis showed that tumor size, mitotic count,tumor location, NIH risk rank, the expression of P16 and CD44 were related to the prognosis of GIST patients.Multivariate showed that tumor size, mitotic count, tumor location, and the expression of CD44 was independent prognosis factors of GIST patients. Conclusion CD44 could be used as a biomarker in predicting the prognosis of GIST patients.

关 键 词：胃肠间质瘤 P16 CD44 预后 组织芯片 

分 类 号：R735[医药卫生—肿瘤]